NCT04899050

Epidiolex in Typical Absence Seizures

Safety and Efficacy of CBD (Epidiolex) in Idiopathic Generalized Epilepsy With Typical Absence Seizures

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: University of South Florida · Academic / Other
• Sex: All
• Age: 6 Years
• Healthy volunteers: Accepted

Summary

This is a Pilot study, open-label study consisting of a screening period of up to 4 weeks, a 4-week dose-titration treatment period to dose of up to 20 mg/kg/day BID of CBD (Epidiolex), and a 30 day safety follow-up period following the last dose of study medication.

Conditions

• Study the Efficacy of Epidiolex for Typical Absence Seizures

Interventions

Type	Name	Description
DRUG	Cannabidiol (Epidiolex)	Use of Epidiolex to control absence seizures.

Timeline

• Start date: 2021-07-30
• Primary completion: 2023-05-27
• Completion: 2023-05-27
• First posted: 2021-05-24
• Last updated: 2023-07-11

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study